UK-based NeuroSolutions, the fully owned subsidiary of NeuroDiscovery (ASX:NDL), has signed its first Australian revenue contract with Perth-based biopharmaceutical company Alzhyme. NeuroSolutions' Alzheimer models will be used to investigate the potential of three Alzhyme peptides to impede the progression of the disease.

Resonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT), has been awarded a health supply contract from the government of Western Australia's department of health, for its FerriScan diagnostic test.